Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.380
-0.060 (-1.74%)
Jul 21, 2025, 2:47 PM - Market open
Anixa Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
108.87M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ANIX News
- 5 days ago - Anixa Biosciences: Oncology Platform With Asymmetric Upside - Seeking Alpha
- 12 days ago - Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology - PRNewsWire
- 4 weeks ago - Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 4 weeks ago - Anixa Biosciences to Host an Investor Webcast on June 26, 2025 - PRNewsWire
- 5 weeks ago - Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage - PRNewsWire
- 6 weeks ago - Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025 - PRNewsWire
- 6 weeks ago - Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview - PRNewsWire
- 7 weeks ago - Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine - PRNewsWire